biostudies-literatureUnknown186(2)Mink van der Molen DR<h4>Purpose</h4>To identify factors associated with (perceived) access to health care among (ex-)breast cancer patients during the COVID-19 pandemic.<h4>Methods</h4>Cross-sectional study within a large prospective, multicenter cohort of (ex-)breast cancer patients, i.e., UMBRELLA. All participants enrolled in the UMBRELLA cohort between October 2013 and April 2020 were sent a COVID-19-specific survey, including the Hospital Anxiety and Depression Scale (HADS) questionnaire.<h4>Results</h4>In total, 1051 (66.0%) participants completed the survey. During COVID-19, 284 (27.0%) participants reported clinically relevant increased levels of anxiety and/or depression, i.e., total HADS score ≥ 12. Participants with anxiety and/or depression reported statistically significant higher barriers to conBreast cancer research and treatment577-583https://www.ebi.ac.uk/biostudies/studies/S-EPMC7889408biostudies-literature(Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic.PMC7889408Ernst MFvan Stam LEBargon CAYoung-Afat DAvan Dam IEBatenburg MCTGal RSchoenmaeckers EJPDoeksen Avan Dalen TBijlsma RMvan der Leij FMaarse WVermulst NVerkooijen HMBaas IOUMBRELLA study groupMink van der Molen DRfalse(Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic.<h4>Purpose</h4>To identify factors associated with (perceived) access to health care among (ex-)breast cancer patients during the COVID-19 pandemic.<h4>Methods</h4>Cross-sectional study within a large prospective, multicenter cohort of (ex-)breast cancer patients, i.e., UMBRELLA. All participants enrolled in the UMBRELLA cohort between October 2013 and April 2020 were sent a COVID-19-specific survey, including the Hospital Anxiety and Depression Scale (HADS) questionnaire.<h4>Results</h4>In total, 1051 (66.0%) participants completed the survey. During COVID-19, 284 (27.0%) participants reported clinically relevant increased levels of anxiety and/or depression, i.e., total HADS score ≥ 12. Participants with anxiety and/or depression reported statistically significant higher barriers to con2021-01-01T00:00:00Z2021 Apr2025-06-01T12:19:11.549Z2021-02-22T08:09:32ZS-EPMC78894083359887910.1007/s10549-021-06112-y